We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Aptevo Therapeutics Inc. (APVO - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aptevo Therapeutics Inc. is one of 1011 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aptevo Therapeutics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for APVO's full-year earnings has moved 65.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, APVO has gained about 15.6% so far this year. Meanwhile, stocks in the Medical group have lost about 3.9% on average. This shows that Aptevo Therapeutics Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Accuray (ARAY - Free Report) . The stock is up 7.6% year-to-date.
The consensus estimate for Accuray's current year EPS has increased 200% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Aptevo Therapeutics Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 513 individual companies and currently sits at #63 in the Zacks Industry Rank. This group has lost an average of 12.6% so far this year, so APVO is performing better in this area.
Accuray, however, belongs to the Medical - Instruments industry. Currently, this 85-stock industry is ranked #87. The industry has moved +7% so far this year.
Aptevo Therapeutics Inc. and Accuray could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Aptevo Therapeutics Inc. (APVO - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aptevo Therapeutics Inc. is one of 1011 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aptevo Therapeutics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for APVO's full-year earnings has moved 65.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, APVO has gained about 15.6% so far this year. Meanwhile, stocks in the Medical group have lost about 3.9% on average. This shows that Aptevo Therapeutics Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Accuray (ARAY - Free Report) . The stock is up 7.6% year-to-date.
The consensus estimate for Accuray's current year EPS has increased 200% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Aptevo Therapeutics Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 513 individual companies and currently sits at #63 in the Zacks Industry Rank. This group has lost an average of 12.6% so far this year, so APVO is performing better in this area.
Accuray, however, belongs to the Medical - Instruments industry. Currently, this 85-stock industry is ranked #87. The industry has moved +7% so far this year.
Aptevo Therapeutics Inc. and Accuray could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.